Praxis Precision Medicines, Inc. (PRAX) AI Stock Analysis
PRAX AI stock analysis summary
AI ResearchPraxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system disorders. The company generated $7.5M in trailing twelve-month revenue while reporting a net loss of -$182.8M in FY2024. As of June 30, 2026, Praxis held $758.6M in cash and short-term investments against total debt of $1.1M.
- Market cap
- $6.75B
- Revenue (TTM)
- $7.5M
- P/E
- —
- 1Y return
- 48.6% S&P 500 16.8%
- Avg. target
- $650.00 168.9% vs last close
Bull case
- Wall Street analysts show strong conviction with 15 Strong Buy ratings and a mean price target of $650.00, representing 168.9% upside from the last close.
- The company maintains solid balance sheet liquidity, holding $758.6M in cash and short-term investments against $1.1M in total debt as of June 30, 2026.
- Quarterly revenue demonstrated rapid momentum, expanding 1349.1% year-over-year in the quarter ended June 30, 2026.
Bear case
- The business remains unprofitable, generating net income of -$182.8M and free cash flow of -$131.8M in FY2024.
- Praxis has substantially diluted existing equity holders, increasing its share count by 871.8% over the past five years.
- Shares trade at a steep price-to-sales multiple of 144.7x, well above the US-listed Healthcare peer median of 4.1x.
What Praxis Precision Medicines does
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalances. Its primary candidate, ulixacaltamide, is a small molecule inhibitor of T-type calcium channels undergoing Phase IIb trials for essential tremor and Phase II trials for Parkinson's disease. The company is also evaluating PRAX-562 for developmental and epileptic encephalopathies, alongside PRAX-628 for focal epilepsy. Additional pipeline programs include PRAX-222, PRAX-020, PRAX-080, PRAX-090, and PRAX-100. Praxis maintains collaborations with partners including RogCon, Ionis Pharmaceuticals, UCB Biopharma, and The Florey Institute.
Growth and profitability
Annual revenue grew from $1.5M in FY2022 to $2.4M in FY2023 and $8.6M in FY2024, reflecting a two-year compound annual growth rate of 141.7%. Operating margins were deeply negative over this period, at -14684.8% in FY2022, -5164.4% in FY2023, and -2340.3% in FY2024. Net income was -$213.1M in FY2022, -$123.3M in FY2023, and -$182.8M in FY2024, resulting in an EPS of -$10.27 in FY2024. Research and development expenses were $152.4M in FY2024. In the latest quarter ended June 30, 2026, quarterly revenue increased 1349.1% year-over-year, while trailing twelve-month revenue reached $7.5M with an EPS of -$12.95.
Balance sheet and cash flow
As of June 30, 2026, Praxis held $758.6M in cash and short-term investments compared to total debt of $1.1M, yielding net cash of $757.5M. Total assets stood at $1.39B and shareholders' equity was $1.34B. The company maintains a current ratio of 15.73 and a debt-to-equity ratio of 0.00. Free cash flow was -$131.8M in FY2024, compared to -$111.2M in FY2023. Capital expenditures were $56,000 in FY2025, and the company's share count expanded by 871.8% over five years.
Valuation and performance
Praxis trades at a price-to-sales multiple of 144.7x and an enterprise value-to-revenue multiple of 110.9x, compared to the median of its US-listed Healthcare peers of 4.1x sales. Its price-to-book ratio is 5.9x. The stock closed at $241.76 on October 16, 2026, which is 23.4% below its 200-day moving average. Over the past year, the stock returned 48.6%, outperforming the S&P 500 return of 16.8%. Over five years, the stock fell 19.5% while the S&P 500 gained 83.0%. The stock carries a beta of 2.81.
What analysts expect
Consensus ratings include 15 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 1 Strong Sell. The mean price target is $650.00, which is 168.9% above the last closing price of $241.76. For the fiscal year ending December 31, 2026, analysts estimate revenue of $830,710 and an EPS of -$14.02. For the next fiscal year, 18 analysts project revenue of $345.1M and an EPS of -$9.49. Praxis beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.
Key risks and what to watch
- Operating cash flow was -$131.8M alongside research and development expenses of $152.4M in FY2024, demonstrating ongoing cash burn.
- Short interest represents 15.0% of the float, reflecting significant market skepticism.
- The stock exhibits high price volatility with a beta of 2.81 and a trading level 23.4% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PRAX AI stock analysis
This page is an AI-written research summary of Praxis Precision Medicines, Inc. (PRAX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PRAX income statement, PRAX balance sheet, PRAX key metrics, PRAX analyst forecast, PRAX chart. See the PRAX stock overview for the latest quote and news.
PRAX AI stock analysis FAQ
Does Praxis Precision Medicines pay a dividend?
Praxis Precision Medicines does not pay a dividend. The company directs its resources toward clinical trials and research and development, which totaled $152.4M in FY2024.
What is the net cash position of Praxis Precision Medicines?
As of June 30, 2026, Praxis held $758.6M in cash and short-term investments and $1.1M in total debt, resulting in a net cash balance of $757.5M.
What are analysts forecasting for PRAX in the upcoming fiscal years?
For the fiscal year ending December 31, 2026, consensus estimates project revenue of $830,710 and an EPS of -$14.02. For the following fiscal year, 18 analysts forecast revenue of $345.1M and an EPS of -$9.49.
How has PRAX performed compared to the S&P 500?
Over the past year, PRAX returned 48.6% versus a 16.8% return for the S&P 500. Over a five-year timeframe, the stock declined 19.5% while the S&P 500 advanced 83.0%.